SynthesisPharmacoEconomics2012
Economic and humanistic burden of external genital warts.
Synthesis in PharmacoEconomics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Ignored and undervalued in public health: a systematic review of health state utility values associated with syphilis infection.Health and quality of life outcomes · 2024Pooled it
- Systematic review of the incidence and prevalence of genital warts.BMC infectious diseases · 2013Pooled it
- Epidemiological trends and economic burden of genital warts in Dutch primary care.BMJ public health · 2025Article
- Development and psychometric properties of the human papillomavirus-quality of life (HPV-QoL) questionnaire to assess the impact of HPV on women health-related-quality-of-life.Archives of gynecology and obstetrics · 2022Article
- Costs and Resource Use Among Patients with Cervical Cancer, Cervical Intraepithelial Neoplasia, and Genital Warts in Algeria.Journal of health economics and outcomes research · 2022Article
- Healthcare resource utilization and costs associated with anogenital warts in Morocco.Infectious agents and cancer · 2021Article
- Position statement for the diagnosis and management of anogenital warts.Journal of the European Academy of Dermatology and Venereology : JEADV · 2019Article
- Estimating the burden of illness related to genital warts in the Philippines: a nationally representative cross-sectional study.Infectious agents and cancer · 2019Article
- Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients.PharmacoEconomics · 2018Article
- Multimodal Counseling Interventions: Effect on Human Papilloma Virus Vaccination Acceptance.Healthcare (Basel, Switzerland) · 2017Article
- A cross-sectional study estimating the burden of illness related to genital warts in South Korea.BMJ open · 2017Article
- Article
- Role of vaccination in the sustainability of healthcare systems.Journal of market access & health policy · 2015Article
- The Economic Value of Vaccination: Why Prevention is Wealth.Journal of market access & health policy · 2015Article
- A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France.Human vaccines & immunotherapeutics · 2013Article
- Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.BMC cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
External genital warts (EGW) are a sexually transmitted infection caused by various strains of human papillomavirus (HPV). Several studies have described the direct and indirect costs of EGW, while others have reported on the burden of EGW in terms of the impact on the quality of life (QOL) of patients. The arrival of a quadrivalent HPV vaccine that protects against both cervical cancer and EGW requires a proper understanding of the impact of vaccines on costs and QOL. Using pre-defined search terms and inclusion/exclusion criteria, we performed a systematic review of the economic and humanistic burden of EGW. The focus of our review was on literature describing the direct and indirect costs of EGW per episode of care (EoC) or per year, as well as the impact of EGW on disease-specific, generic, or preference-based QOL measures. We also reviewed the literature on the national economic burden of EGW from the perspectives of different countries. Other aspects of EGW management that can inform economic modelling studies, such as length of EoC, number of physician visits and indirect costs, were also explored. Our review sheds light on the high economic and humanistic burden of EGW and important differences in the costs between men and women, as well as the differences in health resource utilization and costs across countries. Our study also highlights the dearth of information on the impact of EGW on the QOL and productivity of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.